Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.
Anemia is common in chronic kidney disease (CKD). The CHOIR study found increased risk of a composite cardiovascular outcome when anemia was treated with epoetin-alfa to a target hemoglobin level of 13.5 as compared with 11.3 g/dl. Whether this increase applies to all patient subgroups equally is unclear. We discuss an analysis by Szczech and colleagues of the effects of the higher hemoglobin target in CKD patients with diabetes mellitus or congestive heart failure.
Fishbane
Steven
S
Winthrop-University Hospital, Mineola, New York, USA. sfishbane@metrorenal.com
Miyawaki
Nobuyuki
N
D000740:Anemia / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D003920:Diabetes Mellitus; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects*; D006333:Heart Failure / Q000139:chemically induced* / Q000209:etiology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007674:Kidney Diseases / Q000150:complications*; D011994:Recombinant Proteins
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa